GMP综合症的营销对策(国外英语资料).docVIP

GMP综合症的营销对策(国外英语资料) According to the relevant departments of SFDA statistics, before July 1st, through the GMP certification of pharmaceutical enterprises in about 3100, accounting for 60% of the country. There are 2000 enterprises, nearly 900 workshops were forced to stop production. Enterprises that have passed GMP account for 90% of the domestic pharmaceutical market, and the drugs cover all the commonly used clinical products, which can completely meet the market demand. There is a saying in the industry: but GMP GMP is dead, too! In fact, GMP is not an administrative type of death law; the implementation of GMP is an economic type of death. But there was little news or news that around a number of small and medium enterprises to abandon GMP certification in July 1st after the climax continued, is said by GMP to reduce the repeated low level of the original building is lost! However, small and medium-sized pharmaceutical companies have passed the national GMP certification, but it is difficult to be recognized by the market, generally suffering from GMP syndrome, the following author on this issue, talk about their own thinking and countermeasures. One of the symptoms, operating costs substantially improved 1, the cost of improving the clinical performance (1) the cost of passing GMP is prohibitive It is understood that GMP has more than 80 certification rules, including more than 200 inspection items etc. drug labels and instructions for use, or drug, involves many aspects of software and hardware, management content, the implementation of GMP is a complicated and huge system engineering. According to public information, only the transformation of a factory, enterprises spend less than the amount of millions of funds, more than tens of millions of degrees. According to the survey research center China social economic survey in conjunction with relevant associations China pharmaceutical enterprise competitiveness research group in Sichuan, an area of a total of